AstraZeneca COVID Vaccine Trials Resume After Being Put On Hold | NBC Nightly News

About This Source - NBC News

NBC News is the news division of the American broadcast television network NBC.

NBC News aired the first, regularly scheduled news program in American broadcast television history on February 21, 1940.

Recent from NBC News:

  • Live: Biden, Harris Deliver Remarks On International Women’s Day | NBC News
  • Live: Cuomo Holds Covid Briefing Amid Harassment Allegations | NBC News
  • Taking A Look At Law Enforcement Data Showing Domestic Violence Calls Throughout Pandemic | NBC News
  • NBC News published this video item, entitled “AstraZeneca COVID Vaccine Trials Resume After Being Put On Hold | NBC Nightly News” – below is their description.

    Phase three clinical trials resumed after pausing to review safety data. Around 18,000 people have received the vaccine, which is being developed in partnership with the University of Oxford.» Subscribe to NBC News: » Watch more NBC video: NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and engaging news stories. NBC News Digital features,,, Nightly News, Meet the Press, Dateline, and the existing apps and digital extensions of these respective properties. We deliver the best in breaking news, live video coverage, original journalism and segments from your favorite NBC News Shows. Connect with NBC News Online! NBC News App: Breaking News Alerts: Visit NBCNews.Com: Find NBC News on Facebook: Follow NBC News on Twitter: Follow NBC News on Instagram: AstraZeneca COVID Vaccine Trials Resume After Being Put On Hold | NBC Nightly News

    NBC News YouTube Channel

    Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.

    In This Story: AstraZeneca

    AstraZeneca plc/AB (LON: AZN) is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its headquarters in Cambridge, United Kingdom and Södertälje, Sweden. Its R&D is concentrated in Cambridge in United Kingdom, Södertälje in Sweden, and Maryland and Toronto in North America.

    3 Recent Items: AstraZeneca

  • Scientifically safe but Astrazeneca skeptics remain
  • Coronavirus: Italy approves AstraZeneca vaccine for people over 65 as death toll nears 100,000
  • Coronavirus: Mass AstraZeneca vaccine rollout begins in Victoria | 9 News Australia
  • Leave a Comment